[
    {
        "Title": "Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system.",
        "Journal Name": "The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "PMID": "10407014",
        "PMC": "PMC6783109",
        "DOI": "10.1523/JNEUROSCI.19-14-05731.1999",
        "Release Date": "--",
        "Abstract": "Vascular endothelial growth factor (VEGF) is a mitogen for endothelial cells, and it promotes angiogenesis in vivo. Here we report that VEGF(165) has neurotrophic actions on cultured adult mouse superior cervical ganglia (SCG) and dorsal root ganglia (DRG), measured as axonal outgrowth. Maximal effect was observed at 10-50 ng/ml for SCG and 100 ng/ml for DRG. VEGF-induced axonal outgrowth was inhibited by the mitogen-activated protein kinase kinase inhibitor PD 98059 but not by the protein kinase inhibitor K252a. VEGF also increased survival of both neurons and satellite cells and the number of proliferating Schwann cells. Immunocytochemistry and immunoblotting revealed that VEGF was expressed in virtually all nerve cells in the SCG but only in a population of small-diameter (<35 micrometers) neurons representing approximately 30% of the neurons in DRG. Immunostaining showed that the VEGF receptor fetal liver kinase receptor (flk-1) was found on nerve cell bodies in DRG and to a lesser extent on neurons in SCG. Growth cones of regenerating axons from both types of ganglia exhibited flk-1 immunoreactivity, as did Schwann cells. We conclude that VEGF has both neurotrophic and mitogenic activity on cells in the peripheral nervous system.",
        "Query": "(ENG[Language]) AND (pubmed pmc[Subset]) AND (\"FLK1\") AND (\"4,6-Pteridinediol, 2-amino-\") NOT (Retracted Publication[pt])",
        "Query_DrugName": "4,6-Pteridinediol, 2-amino-",
        "Query_ProteinName": "FLK1"
    },
    {
        "Title": "Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents.",
        "Journal Name": "Bioorganic & medicinal chemistry",
        "PMID": "20558072",
        "PMC": "PMC2910361",
        "DOI": "10.1016/j.bmc.2010.05.049",
        "Release Date": "25-05-2010",
        "Abstract": "A series of 2-amino-4-m-bromoanilino-6-benzyl pyrrolo[2,3-d]pyrimidines analogues 4-12 were synthesized and evaluated as inhibitors of receptor tyrosine kinases (RTKs). These analogues were synthesized from the appropriate alpha-bromomethylbenzylketones via cyclocondensation with 2,6-diamino-4-pyrimidone to afford the 2-amino-4-oxo-6-substituted benzyl pyrrolo[2,3-d]pyrimidines. Chlorination at the 4-position followed by displacement with 3-bromoaniline or 3-bromo-N-methylaniline and methylation of the 7-NH afforded the target compounds. Remarkably, dimethylation of both the 4-N and N7 afford whole cell EGFR inhibitors that are more cytotoxic than clinically used erlotinib and mono-methylation at the 4-N or N7 affords more cytotoxic whole cell PDGFR-beta inhibitors than clinically used sunitinib. Methylation at either the 4-N or N7 position was detrimental to whole cell VEGFR-2 inhibition. The inhibitory data against the RTKs in this study demonstrates that methylation of the 4-NH and/or the 7-NH influences both the specificity and potency of RTK inhibition.",
        "Query": "(ENG[Language]) AND (pubmed pmc[Subset]) AND (\"Vascular endothelial growth factor receptor 2\") AND (\"2-Amino-4,6-dihydroxypteridine\") NOT (Retracted Publication[pt])",
        "Query_DrugName": "2-Amino-4,6-dihydroxypteridine",
        "Query_ProteinName": "Vascular endothelial growth factor receptor 2"
    },
    {
        "Title": "Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents.",
        "Journal Name": "Bioorganic & medicinal chemistry",
        "PMID": "20558072",
        "PMC": "PMC2910361",
        "DOI": "10.1016/j.bmc.2010.05.049",
        "Release Date": "25-05-2010",
        "Abstract": "A series of 2-amino-4-m-bromoanilino-6-benzyl pyrrolo[2,3-d]pyrimidines analogues 4-12 were synthesized and evaluated as inhibitors of receptor tyrosine kinases (RTKs). These analogues were synthesized from the appropriate alpha-bromomethylbenzylketones via cyclocondensation with 2,6-diamino-4-pyrimidone to afford the 2-amino-4-oxo-6-substituted benzyl pyrrolo[2,3-d]pyrimidines. Chlorination at the 4-position followed by displacement with 3-bromoaniline or 3-bromo-N-methylaniline and methylation of the 7-NH afforded the target compounds. Remarkably, dimethylation of both the 4-N and N7 afford whole cell EGFR inhibitors that are more cytotoxic than clinically used erlotinib and mono-methylation at the 4-N or N7 affords more cytotoxic whole cell PDGFR-beta inhibitors than clinically used sunitinib. Methylation at either the 4-N or N7 position was detrimental to whole cell VEGFR-2 inhibition. The inhibitory data against the RTKs in this study demonstrates that methylation of the 4-NH and/or the 7-NH influences both the specificity and potency of RTK inhibition.",
        "Query": "(ENG[Language]) AND (pubmed pmc[Subset]) AND (\"VEGFR2\") AND (\"2-Amino-4,6-pteridinediol\") NOT (Retracted Publication[pt])",
        "Query_DrugName": "2-Amino-4,6-pteridinediol",
        "Query_ProteinName": "VEGFR2"
    },
    {
        "Title": "Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents.",
        "Journal Name": "Bioorganic & medicinal chemistry",
        "PMID": "20558072",
        "PMC": "PMC2910361",
        "DOI": "10.1016/j.bmc.2010.05.049",
        "Release Date": "25-05-2010",
        "Abstract": "A series of 2-amino-4-m-bromoanilino-6-benzyl pyrrolo[2,3-d]pyrimidines analogues 4-12 were synthesized and evaluated as inhibitors of receptor tyrosine kinases (RTKs). These analogues were synthesized from the appropriate alpha-bromomethylbenzylketones via cyclocondensation with 2,6-diamino-4-pyrimidone to afford the 2-amino-4-oxo-6-substituted benzyl pyrrolo[2,3-d]pyrimidines. Chlorination at the 4-position followed by displacement with 3-bromoaniline or 3-bromo-N-methylaniline and methylation of the 7-NH afforded the target compounds. Remarkably, dimethylation of both the 4-N and N7 afford whole cell EGFR inhibitors that are more cytotoxic than clinically used erlotinib and mono-methylation at the 4-N or N7 affords more cytotoxic whole cell PDGFR-beta inhibitors than clinically used sunitinib. Methylation at either the 4-N or N7 position was detrimental to whole cell VEGFR-2 inhibition. The inhibitory data against the RTKs in this study demonstrates that methylation of the 4-NH and/or the 7-NH influences both the specificity and potency of RTK inhibition.",
        "Query": "(ENG[Language]) AND (pubmed pmc[Subset]) AND (\"VEGFR2\") AND (\"2-Amino-4,6-dihydroxypteridine\") NOT (Retracted Publication[pt])",
        "Query_DrugName": "2-Amino-4,6-dihydroxypteridine",
        "Query_ProteinName": "VEGFR2"
    },
    {
        "Title": "BMS794833 inhibits macrophage efferocytosis by directly binding to MERTK and inhibiting its activity.",
        "Journal Name": "Experimental & molecular medicine",
        "PMID": "36056187",
        "PMC": "PMC9534909",
        "DOI": "10.1038/s12276-022-00840-x",
        "Release Date": "02-09-2022",
        "Abstract": "Myeloid epithelial reproductive proto-oncogene tyrosine kinase (MERTK) plays an essential role in modulating cancer immune tolerance by regulating macrophage efferocytosis. Studies are underway to develop small-molecule chemicals that inhibit MERTK as cancer immunotherapeutic agents, but these efforts are in their early stages. This study identified BMS794833, whose primary targets are MET and VEGFR2, as a potent MERTK inhibitor and developed a real-time efferocytosis monitoring system. The X-ray cocrystal structure revealed that BMS794833 was in contact with the ATP-binding pocket and the allosteric back pocket, rendering MERTK inactive. Homogeneous time-resolved fluorescence kinetic and Western blotting analyses showed that BMS794833 competitively inhibited MERTK activity in vitro and inhibited the autophosphorylation of MERTK in macrophages. We developed a system to monitor MERTK-dependent efferocytosis in real time, and using this system, we confirmed that BMS794833 significantly inhibited the efferocytosis of differentiated macrophages. Finally, BMS794833 significantly inhibited efferocytosis in vivo in a mouse model. These data show that BMS794833 is a type II MERTK inhibitor that regulates macrophage efferocytosis. In addition, the real-time efferocytosis monitoring technology developed in this study has great potential for future applications.",
        "Query": "(ENG[Language]) AND (pubmed pmc[Subset]) AND (\"VEGFR2\") AND (\"4,6-Pteridinediol, 2-amino-\") NOT (Retracted Publication[pt])",
        "Query_DrugName": "4,6-Pteridinediol, 2-amino-",
        "Query_ProteinName": "VEGFR2"
    },
    {
        "Title": "Phorbol esters induce PLVAP expression via VEGF and additional secreted molecules in MEK1-dependent and p38, JNK and PI3K/Akt-independent manner.",
        "Journal Name": "Journal of cellular and molecular medicine",
        "PMID": "30394679",
        "PMC": "PMC6349158",
        "DOI": "10.1111/jcmm.13993",
        "Release Date": "05-11-2018",
        "Abstract": "Endothelial diaphragms are subcellular structures critical for mammalian survival with poorly understood biogenesis. Plasmalemma vesicle associated protein (PLVAP) is the only known diaphragm component and is necessary for diaphragm formation. Very little is known about PLVAP regulation. Phorbol esters (PMA) are known to induce de novo PLVAP expression and diaphragm formation. We show that this induction relies on the de novo production of soluble factors that will act in an autocrine manner to induce PLVAP transcription and protein expression. We identified vascular endothelial growth factor-A (VEGF-A) signalling through VEGFR2 as a necessary but not sufficient downstream event as VEGF-A inhibition with antibodies and siRNA or pharmacological inhibition of VEGFR2 only partially inhibit PLVAP upregulation. In terms of downstream pathways, inhibition of MEK1/Erk1/2 MAP kinase blocked PLVAP upregulation, whereas inhibition of p38 and JNK MAP kinases or PI3K and Akt had no effect on PMA-induced PLVAP expression. In conclusion, we show that VEGF-A along with other secreted proteins act synergistically to up-regulate PLVAP in MEK1/Erk1/2 dependent manner, bringing us one step further into understanding the genesis of the essential structures that are endothelial diaphragms.",
        "Query": "(ENG[Language]) AND (pubmed pmc[Subset]) AND (\"VEGFR2\") AND (\"4,6-Pteridinediol, 2-amino-\") NOT (Retracted Publication[pt])",
        "Query_DrugName": "4,6-Pteridinediol, 2-amino-",
        "Query_ProteinName": "VEGFR2"
    },
    {
        "Title": "Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents.",
        "Journal Name": "Bioorganic & medicinal chemistry",
        "PMID": "20558072",
        "PMC": "PMC2910361",
        "DOI": "10.1016/j.bmc.2010.05.049",
        "Release Date": "25-05-2010",
        "Abstract": "A series of 2-amino-4-m-bromoanilino-6-benzyl pyrrolo[2,3-d]pyrimidines analogues 4-12 were synthesized and evaluated as inhibitors of receptor tyrosine kinases (RTKs). These analogues were synthesized from the appropriate alpha-bromomethylbenzylketones via cyclocondensation with 2,6-diamino-4-pyrimidone to afford the 2-amino-4-oxo-6-substituted benzyl pyrrolo[2,3-d]pyrimidines. Chlorination at the 4-position followed by displacement with 3-bromoaniline or 3-bromo-N-methylaniline and methylation of the 7-NH afforded the target compounds. Remarkably, dimethylation of both the 4-N and N7 afford whole cell EGFR inhibitors that are more cytotoxic than clinically used erlotinib and mono-methylation at the 4-N or N7 affords more cytotoxic whole cell PDGFR-beta inhibitors than clinically used sunitinib. Methylation at either the 4-N or N7 position was detrimental to whole cell VEGFR-2 inhibition. The inhibitory data against the RTKs in this study demonstrates that methylation of the 4-NH and/or the 7-NH influences both the specificity and potency of RTK inhibition.",
        "Query": "(ENG[Language]) AND (pubmed pmc[Subset]) AND (\"VEGFR\") AND (\"2-Amino-4,6-pteridinediol\") NOT (Retracted Publication[pt])",
        "Query_DrugName": "2-Amino-4,6-pteridinediol",
        "Query_ProteinName": "VEGFR"
    },
    {
        "Title": "Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents.",
        "Journal Name": "Bioorganic & medicinal chemistry",
        "PMID": "20558072",
        "PMC": "PMC2910361",
        "DOI": "10.1016/j.bmc.2010.05.049",
        "Release Date": "25-05-2010",
        "Abstract": "A series of 2-amino-4-m-bromoanilino-6-benzyl pyrrolo[2,3-d]pyrimidines analogues 4-12 were synthesized and evaluated as inhibitors of receptor tyrosine kinases (RTKs). These analogues were synthesized from the appropriate alpha-bromomethylbenzylketones via cyclocondensation with 2,6-diamino-4-pyrimidone to afford the 2-amino-4-oxo-6-substituted benzyl pyrrolo[2,3-d]pyrimidines. Chlorination at the 4-position followed by displacement with 3-bromoaniline or 3-bromo-N-methylaniline and methylation of the 7-NH afforded the target compounds. Remarkably, dimethylation of both the 4-N and N7 afford whole cell EGFR inhibitors that are more cytotoxic than clinically used erlotinib and mono-methylation at the 4-N or N7 affords more cytotoxic whole cell PDGFR-beta inhibitors than clinically used sunitinib. Methylation at either the 4-N or N7 position was detrimental to whole cell VEGFR-2 inhibition. The inhibitory data against the RTKs in this study demonstrates that methylation of the 4-NH and/or the 7-NH influences both the specificity and potency of RTK inhibition.",
        "Query": "(ENG[Language]) AND (pubmed pmc[Subset]) AND (\"VEGFR\") AND (\"2-Amino-4,6-dihydroxypteridine\") NOT (Retracted Publication[pt])",
        "Query_DrugName": "2-Amino-4,6-dihydroxypteridine",
        "Query_ProteinName": "VEGFR"
    },
    {
        "Title": "Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in NaÃ¯ve and Anti-PD-1 Resistant CT26-Bearing Mice.",
        "Journal Name": "International journal of molecular sciences",
        "PMID": "36142591",
        "PMC": "PMC9504159",
        "DOI": "10.3390/ijms231810677",
        "Release Date": "14-09-2022",
        "Abstract": "Combined inhibition of vascular endothelial growth factor receptor (VEGFR) and the programmed cell death protein 1 (PD-1) pathways has shown efficacy in multiple cancers; however, the clinical outcomes show limited benefits and the unmet clinical needs still remain and require improvement in efficacy. Using murine colon carcinoma (CT26) allograft models, we examined the efficacy and elucidated novel tumor microenvironment (TME) remodeling mechanisms underlying the combination of chidamide (a benzamide-based class l histone deacetylase inhibitor; brand name in Taiwan, Kepida",
        "Query": "(ENG[Language]) AND (pubmed pmc[Subset]) AND (\"VEGFR\") AND (\"4,6-Pteridinediol, 2-amino-\") NOT (Retracted Publication[pt])",
        "Query_DrugName": "4,6-Pteridinediol, 2-amino-",
        "Query_ProteinName": "VEGFR"
    },
    {
        "Title": "Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents.",
        "Journal Name": "Bioorganic & medicinal chemistry",
        "PMID": "20558072",
        "PMC": "PMC2910361",
        "DOI": "10.1016/j.bmc.2010.05.049",
        "Release Date": "25-05-2010",
        "Abstract": "A series of 2-amino-4-m-bromoanilino-6-benzyl pyrrolo[2,3-d]pyrimidines analogues 4-12 were synthesized and evaluated as inhibitors of receptor tyrosine kinases (RTKs). These analogues were synthesized from the appropriate alpha-bromomethylbenzylketones via cyclocondensation with 2,6-diamino-4-pyrimidone to afford the 2-amino-4-oxo-6-substituted benzyl pyrrolo[2,3-d]pyrimidines. Chlorination at the 4-position followed by displacement with 3-bromoaniline or 3-bromo-N-methylaniline and methylation of the 7-NH afforded the target compounds. Remarkably, dimethylation of both the 4-N and N7 afford whole cell EGFR inhibitors that are more cytotoxic than clinically used erlotinib and mono-methylation at the 4-N or N7 affords more cytotoxic whole cell PDGFR-beta inhibitors than clinically used sunitinib. Methylation at either the 4-N or N7 position was detrimental to whole cell VEGFR-2 inhibition. The inhibitory data against the RTKs in this study demonstrates that methylation of the 4-NH and/or the 7-NH influences both the specificity and potency of RTK inhibition.",
        "Query": "(ENG[Language]) AND (pubmed pmc[Subset]) AND (\"VEGFR\") AND (\"4,6-Pteridinediol, 2-amino-\") NOT (Retracted Publication[pt])",
        "Query_DrugName": "4,6-Pteridinediol, 2-amino-",
        "Query_ProteinName": "VEGFR"
    },
    {
        "Title": "Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents.",
        "Journal Name": "Bioorganic & medicinal chemistry",
        "PMID": "20558072",
        "PMC": "PMC2910361",
        "DOI": "10.1016/j.bmc.2010.05.049",
        "Release Date": "25-05-2010",
        "Abstract": "A series of 2-amino-4-m-bromoanilino-6-benzyl pyrrolo[2,3-d]pyrimidines analogues 4-12 were synthesized and evaluated as inhibitors of receptor tyrosine kinases (RTKs). These analogues were synthesized from the appropriate alpha-bromomethylbenzylketones via cyclocondensation with 2,6-diamino-4-pyrimidone to afford the 2-amino-4-oxo-6-substituted benzyl pyrrolo[2,3-d]pyrimidines. Chlorination at the 4-position followed by displacement with 3-bromoaniline or 3-bromo-N-methylaniline and methylation of the 7-NH afforded the target compounds. Remarkably, dimethylation of both the 4-N and N7 afford whole cell EGFR inhibitors that are more cytotoxic than clinically used erlotinib and mono-methylation at the 4-N or N7 affords more cytotoxic whole cell PDGFR-beta inhibitors than clinically used sunitinib. Methylation at either the 4-N or N7 position was detrimental to whole cell VEGFR-2 inhibition. The inhibitory data against the RTKs in this study demonstrates that methylation of the 4-NH and/or the 7-NH influences both the specificity and potency of RTK inhibition.",
        "Query": "(ENG[Language]) AND (pubmed pmc[Subset]) AND (\"VEGFR-2\") AND (\"2-Amino-4,6-dihydroxypteridine\") NOT (Retracted Publication[pt])",
        "Query_DrugName": "2-Amino-4,6-dihydroxypteridine",
        "Query_ProteinName": "VEGFR-2"
    },
    {
        "Title": "Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents.",
        "Journal Name": "Bioorganic & medicinal chemistry",
        "PMID": "20558072",
        "PMC": "PMC2910361",
        "DOI": "10.1016/j.bmc.2010.05.049",
        "Release Date": "25-05-2010",
        "Abstract": "A series of 2-amino-4-m-bromoanilino-6-benzyl pyrrolo[2,3-d]pyrimidines analogues 4-12 were synthesized and evaluated as inhibitors of receptor tyrosine kinases (RTKs). These analogues were synthesized from the appropriate alpha-bromomethylbenzylketones via cyclocondensation with 2,6-diamino-4-pyrimidone to afford the 2-amino-4-oxo-6-substituted benzyl pyrrolo[2,3-d]pyrimidines. Chlorination at the 4-position followed by displacement with 3-bromoaniline or 3-bromo-N-methylaniline and methylation of the 7-NH afforded the target compounds. Remarkably, dimethylation of both the 4-N and N7 afford whole cell EGFR inhibitors that are more cytotoxic than clinically used erlotinib and mono-methylation at the 4-N or N7 affords more cytotoxic whole cell PDGFR-beta inhibitors than clinically used sunitinib. Methylation at either the 4-N or N7 position was detrimental to whole cell VEGFR-2 inhibition. The inhibitory data against the RTKs in this study demonstrates that methylation of the 4-NH and/or the 7-NH influences both the specificity and potency of RTK inhibition.",
        "Query": "(ENG[Language]) AND (pubmed pmc[Subset]) AND (\"VEGFR-2\") AND (\"4,6-Pteridinediol, 2-amino-\") NOT (Retracted Publication[pt])",
        "Query_DrugName": "4,6-Pteridinediol, 2-amino-",
        "Query_ProteinName": "VEGFR-2"
    }
]